Reuters logo
BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL
October 23, 2017 / 8:33 PM / in a month

BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL

Oct 23 (Reuters) - Morphosys AG -

* DGAP-Adhoc: Adhoc: Morphosys receives FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL

* Morphosys AG says ‍receives FDA breakthrough therapy designation for its antibody MOR208 in relapsed/refractory DLBCL​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below